Key Takeaways
- Steady quarter, mix shift underway: Revenue was steady, but custom synthesis jumped from 40% to 46% of the mix as two major big-pharma projects entered full-scale production, lifting gross margins by 200 bps.
- Generic pricing pressure is cyclical, not structural: Management frames the current pressure as a 4-5 year competitor destocking cycle; Divi's has gained 3-5% market share through it and expects stability in 2-3 quarters.
- The next growth wave is visible but distant: Contrast media and GLP-1 building blocks are in active qualification with innovators, but management points to 2025 for material revenue contribution, with a ~1-year lag after qualifications complete.
- Kakinada is the FY25 growth unlock: The greenfield site begins production by end-Q2 FY25 and commercialization by end-Q3 FY25, with management guiding for double-digit revenue growth year-on-year as it comes online.
- What to watch next quarter: The pace of qualification approvals for GLP-1 and contrast media, the trajectory of Red Sea freight costs, and any early signals on Kakinada's regulatory timeline.
Custom Synthesis: The Mix Shift in Motion
- Two projects hit full-scale production: Two major custom synthesis projects from big pharma entered commercial production this quarter, driving the CS revenue share from 40% to 46% QoQ. Further contribution increases are expected as volumes scale.
- Both projects are under patent: Management confirmed the molecules are still patent-protected and being produced for innovators, but declined to break down whether they are novel or late-lifecycle management projects, citing confidentiality.
- Gross margin tailwind: The 200 bps gross margin improvement was driven by the higher CS mix and softening raw material prices, a trend management expects to continue. The exact split between the two drivers was not quantified.
- Post-patent strategy is a moat: When products go off patent, Divi's works with innovators on late life-cycle management, bringing more cost-effective routes and re-qualifying new processes to help them keep market share. This re-qualification cycle creates a recurring opportunity.
Dr. Kiran S. Divi: "During that process, we bring the most effective route, we discuss with the innovator in hand, and then we work with them in re-qualifying this new process which is more cost effective and helping them to keep the market share."
Generic Business: Pricing Pressure and Market Share
- Pricing pressure is a destocking cycle: Management described the current generic pricing pressure as a cycle that occurs every 4-5 years when competitors destock products, causing price drops across global markets. Stability is expected in the next 2-3 quarters once destocking ends.
- Market share gained, not lost: Despite the pricing environment, Divi's has maintained and gained 3% to 5% market share in most of its large-volume APIs. Sustained demand for established products continues.
- Material costs easing: Material consumption fell to 39% of revenue, down from prior levels, due to a favorable product mix and softening raw material prices.
- Q3 seasonality: Management noted Q3 is typically a slower quarter for the business compared to other quarters.
Dr. Kiran S. Divi: "The generic business, in general, we have not lost any market share. In fact, we have gained market share in several of our large-volume APIs."
Contrast Media & GLP-1: The 2025 Opportunity
- Contrast media advantage is cost and quality: Divi's starts chemistry from iodine, recovers iodine, and achieves high atom-to-atom efficiency, making it superior in cost and quality versus Chinese competition in regulated markets. Current strength is in Iopamidol and Iohexol; gadolinium compounds are under qualification with innovators.
- GLP-1 supply chain role: The company is actively involved in protected amino acids, dipeptides, and tripeptides for GLP-1 drugs, supplying and under qualification with innovators. Management declined to name specific drugs or quantify the building block cost as a percentage of API cost, calling it sensitive information.
- Dedicated GLP-1 capacity built: Capacity for existing and projected customer demand is already constructed and undergoing qualification. If volumes exceed current expectations, additional capex will be required.
- Timeline points to 2025: Qualification is a ~1-year process once underway, involving impurity profiles and filings. Management stated, "from 2025, we will start seeing some good numbers on both the fronts (contrast media and GLP-1) and positive results."
- No single growth engine: When asked which would be bigger over five years, management declined to compare, stating the company has about seven growth engines and cannot say which is largest.
Dr. Kiran S. Divi: "We start our chemistry right from Iodine. We know the art of recovering Iodine thereby bring our costs down. And that's why we are efficient in atom-to-atom efficiency. So, price-wise, cost-wise, and quality, we are much more superior in the generic market and that's where a lot of people are qualifying and moving."
Kakinada: The Capacity Catalyst
- Timeline set: Seven production blocks built with ₹458 crores investment. Production activity starts around end of Q2 FY25, with commercialization expected by end of Q3 FY25, subject to regulatory approvals.
- Revenue impact: Management guided that with Kakinada adding to the portfolio in FY25, double-digit year-on-year revenue growth is foreseen.
- Ramp-up cadence: The typical cycle from building a block to full commercialization is two years, suggesting a gradual contribution build rather than a step-change.
- Future capex signal: As opportunities with big pharma increase and Kakinada receives regulatory approvals, further investments will follow.
Margins, Costs & Headwinds
- Gross margin improved 200 bps: Driven by higher custom synthesis mix and softening raw material prices, a trend expected to continue. Management declined to quantify the split between the two drivers.
- Red Sea disruption is a live headwind: The crisis began end-November and partially impacted Q3 through increased freight costs, mandatory war risk insurance, and rerouting delays. Reports indicate a 30% spike in freight cost, and management expects high impact on logistics and supply chain costs going forward. No shipment delays occurred in Q3, but future quarters may be affected.
- Forex gain declined: ₹18 crores in Q3 FY24 versus ₹47 crores in Q3 FY23.
- Margin trajectory context: Management noted pre-COVID, during-COVID, and post-COVID are three different scenarios. Post-COVID, the company is establishing new products and markets with increased logistical costs affecting margins, but this is not seen as long-term.
- Backward integration hope: Management expressed hope for better margins in the near future through backward integration and green chemistry initiatives.
Nutraceuticals & Other Businesses
- Nutraceuticals running at full capacity: Products include Astaxanthin (80% market share), Canthaxanthin, Beta Carotene, and Vitamin D3. Global consumption of natural products has slightly declined, but no market share has been lost. Double-digit growth is being seen, and capacity may be added if opportunities increase.
- Unit 3 infrastructure ongoing: Production activity in the 200-acre Phase I greenfield project will commence in Q2 of FY25.
- Two branded molecules commercialized: Two products under patent are now being produced for innovators.
- Capacity utilization at ~80%: Built capacity is operational; in some cases, qualifications are ongoing with commercial realizations expected in near quarters.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Generic pricing stability | Competitor destocking cycle ends, pricing stabilizes | Next 2-3 quarters |
| Kakinada production start | Production activity begins at greenfield site | End of Q2 FY25 |
| Kakinada commercialization | Commercial production begins, subject to regulatory approvals | End of Q3 FY25 |
| Revenue growth | Double-digit year-on-year growth with Kakinada contribution | FY25 |
| GLP-1/contrast media contribution | "Good numbers" and "positive results" from both fronts | From 2025 |
| Patent expiry products | One or two patents expire, products begin commercializing | 2025, with more in 2026-2028 |
| Custom synthesis contribution | Further increase from two major projects as volumes scale | Coming quarters |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Consolidated total income | ₹1,950 cr, vs ₹1,821 cr in Q3 FY23 and ₹1,995 cr in Q2 FY24 |
| Profit before tax | ₹489 cr |
| Profit after tax | ₹358 cr |
| Material consumption | 39% of revenue, down due to favorable product mix and softening raw material prices |
| Forex gain | ₹18 cr, vs ₹47 cr in Q3 FY23 |
| Constant currency growth (quarter) | 7% |
| Constant currency growth (9 months) | negative 10% |
| Exports share | ~87% of revenue; exports to Europe and America at ~71% |
| Product mix (generics to custom synthesis) | 54% to 46%, vs 60% to 40% in Q2 FY24 |
| Nutraceutical business revenue | ₹153 cr |
| Capacity utilization | ~80% |
| Kakinada investment during FY24 | ₹458 cr, 7 production blocks built |
| Market share gain in large-volume generic products | 3% to 5% |
| Nutraceutical business growth | ~10% steady growth year on year |
| GLP-1 dedicated capacity | several hundreds of tonnes |